Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 1/20 | 0.50 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 9/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2796641 | 0.78 | ALDH1A1 (0.44) | CYP3A4CYP2D6CYP2C19SMN1; SMN2 | |
| SCHEMBL4604214 | 0.76 | TACR1 (0.44) | SIGMAR1CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL17269799 | 0.73 | EPHX2 (0.42) | CYP2C9 | |
| SCHEMBL3098636 | 0.72 | OPRL1 (0.38) | CYP3A4CYP2D6CYP2C9CYP2C19TSHR | |
| Hydrochloric Acid SCHEMBL17262484 | 0.72 | EPHX2 (0.41) | CYP2C9 | |
| SCHEMBL15537060 | 0.70 | SLC6A2 (0.49) | PRMT5WDR77SIGMAR1CYP3A4CYP2D6 | |
| SCHEMBL19603375 | 0.69 | TACR1 (0.34) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4980744 | 0.69 | PRMT5 (0.64) | PRMT5WDR77SIGMAR1CYP3A4CYP2D6 | |
| SCHEMBL1220897 | 0.69 | SLC6A2 (0.50) | SIGMAR1CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL5021635 | 0.69 | ALDH1A1 (0.50) | CYP2D6SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110319424-A1 | NAPHTHYRIDIN-2(1H) -ONE COMPOUNDS USEFUL AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2011-12-29 | — | — | US | disclosed |
| EP-2238135-A1 | NAPHTHYRIDIN-2(1H) -ONE COMPOUNDS USEFUL AS ANTIBACTERIALS | Glaxo Group Limited (GB) | 2010-10-13 | — | — | EP | disclosed |
| WO-2009090222-A1 | NAPHTHYRIDIN-2(1H) -ONE COMPOUNDS USEFUL AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2009-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319424-A1 | NAPHTHYRIDIN-2(1H) -ONE COMPOUNDS USEFUL AS ANTIBACTERIALS | RIF1, MRPL21, NAT1 | PRMT5 1877/4885WDR77 3368/4885SIGMAR1 1314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.